Neurocrine Biosciences has been upgraded to a Zacks Rank #1 (Strong Buy) following a wave of upward earnings estimate revisions over the past 60 days. Current quarter EPS estimates have risen 23.6% to $2.25, next quarter estimates climbed 10.3% to $2.46, current fiscal year estimates improved 18.4% to $9.47, and next fiscal year estimates increased 13.8% to $10.79. The company generated $2.86 billion in annual revenue during 2025, a 22% year-over-year increase, driven by its flagship movement-disorder treatment INGREZZA, and management guided for $2.7 billion to $2.8 billion in INGREZZA sales in 2026. Analysts project total revenue will climb 31% this year to $3.75 billion and another 16% in fiscal year 2027 to $4.34 billion. Shares trade at roughly 17 times forward earnings, a modest multiple for a biotech company expected to deliver double-digit earnings growth, and the company holds approximately $2.5 billion in liquidity.
Neurocrine Biosciences IncAnalysts raised EPS estimates and Zacks gave Strong Buy rating, indicating positive earnings momentum.
Indivior PLC Ordinary Shares
United Therapeutics Corporation
Collegium Pharmaceutical Inc